Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (8-oxo-7-((5-(trifluoromethyl)-1,3-benzothiazol-2-yl)methyl)-7,8- Dihydropyrazino(2,3-d)pyridazin-5-yl)acetic Acid
2. 7,8-dihydro-8-oxo-7-((5-(trifluoromethyl)-2-benzothiazolyl)methyl)pyrazino(2,3-d)pyridazine-5-acetic Acid
3. At-001
4. At001
5. Caficrestat
1. 1355612-71-3
2. Caficrestat
3. At-001
4. Caficrestat [usan]
5. E8i3o45ddu
6. 2-[5-oxo-6-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]pyrazino[2,3-d]pyridazin-8-yl]acetic Acid
7. 7,8-dihydro-8-oxo-7-((5-(trifluoromethyl)-2-benzothiazolyl)methyl)pyrazino(2,3-d)pyridazine-5-acetic Acid
8. Pyrazino(2,3-d)pyridazine-5-acetic Acid, 7,8-dihydro-8-oxo-7-((5-(trifluoromethyl)-2-benzothiazolyl)methyl)-
9. Pyrazino[2,3-d]pyridazine-5-acetic Acid, 7,8-dihydro-8-oxo-7-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-
10. Caficrestat [inn]
11. Unii-e8i3o45ddu
12. Schembl359604
13. At 001 [who-dd]
14. Chembl4297455
15. Yrgpaxavtdmkdk-uhfffaoysa-n
16. At001
17. Ex-a4257
18. Who 11609
19. Akos030526447
20. Cs-5128
21. Db15121
22. Ncgc00484072-01
23. Hy-18967
24. Ms-27395
25. F85302
26. A927584
27. (8-oxo-7-{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl}-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetic Acid
28. 2-(8-oxo-7-((5-(trifluoromethyl)benzo(d)thiazol-2-yl)methyl)-7,8-dihydropyrazino(2,3-d)pyridazin-5-yl) Acetic Acid
29. 2-(8-oxo-7-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetic Acid
| Molecular Weight | 421.4 g/mol |
|---|---|
| Molecular Formula | C17H10F3N5O3S |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 4 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 137 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 706 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
43
PharmaCompass offers a list of Caficrestat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Caficrestat manufacturer or Caficrestat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Caficrestat manufacturer or Caficrestat supplier.
A Aldose reductase-IN-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aldose reductase-IN-1, including repackagers and relabelers. The FDA regulates Aldose reductase-IN-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aldose reductase-IN-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aldose reductase-IN-1 supplier is an individual or a company that provides Aldose reductase-IN-1 active pharmaceutical ingredient (API) or Aldose reductase-IN-1 finished formulations upon request. The Aldose reductase-IN-1 suppliers may include Aldose reductase-IN-1 API manufacturers, exporters, distributors and traders.
Aldose reductase-IN-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aldose reductase-IN-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aldose reductase-IN-1 GMP manufacturer or Aldose reductase-IN-1 GMP API supplier for your needs.
A Aldose reductase-IN-1 CoA (Certificate of Analysis) is a formal document that attests to Aldose reductase-IN-1's compliance with Aldose reductase-IN-1 specifications and serves as a tool for batch-level quality control.
Aldose reductase-IN-1 CoA mostly includes findings from lab analyses of a specific batch. For each Aldose reductase-IN-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aldose reductase-IN-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (Aldose reductase-IN-1 EP), Aldose reductase-IN-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aldose reductase-IN-1 USP).
